Switch from EFV + ZDV-3TC versus EFV + TDF-FTC

COMET Trial
Switch from Efavirenz + AZT-3TC to Efavirenz + TDF-FTC

COMET: Study Design

**Study Design: COMET Study**

- **Background:** Prospective, single-arm 24-week phase 4 switch study evaluating of switching from twice daily zidovudine-lamivudine to once daily tenofovir DF-emtricitabine in virologically suppressed patients on efavirenz

- **Inclusion Criteria** \( n = 402 \)
  - Age ≥18 years
  - On EFV + ZDV-3TC for ≥8 weeks
  - HIV RNA <400 copies/mL
  - CrCl ≥ 50 mL/min

- **Treatment (Switch) Arm**
  - Efavirenz-tenofovir DF-emtricitabine

Switch from Efavirenz + AZT-3TC to Efavirenz + TDF-FTC

COMET: Result

Week 24: Virologic Response

![Virologic Suppression Graph]

Virologic Suppression (%)

- **HIV <400 copies/mL**
  - Baseline: 100/402
  - 24 Weeks: 87/350

- **HIV <50 copies/mL**
  - Baseline: 71/285
  - 24 Weeks: 74/298

Switch from Efavirenz + AZT-3TC to Efavirenz + TDF-FTC

COMET: Result

Week 24: Immunologic Response

Switch from Efavirenz + AZT-3TC to Efavirenz + TDF-FTC

COMET: Result

Week 24: Patient-Reported Outcomes

<table>
<thead>
<tr>
<th>Patient Outcomes</th>
<th>Baseline</th>
<th>24 Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Week Adherence</td>
<td>77</td>
<td>86</td>
</tr>
<tr>
<td>1 Month Adherence</td>
<td>78</td>
<td>86</td>
</tr>
<tr>
<td>General Satisfaction</td>
<td>58</td>
<td>85</td>
</tr>
<tr>
<td>Tolerability</td>
<td>63</td>
<td>83</td>
</tr>
</tbody>
</table>

**Interpretation:** “Patients switched to EFV + TDF/FTC maintained virologic suppression and the regimen was well tolerated. Patients reported increased satisfaction with treatment and fewer were bothered by side effects.”
The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.